Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.
about
STEPWISE - STructured lifestyle Education for People WIth SchizophrEnia: a study protocol for a randomised controlled trial.A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach.The Relationship between Body Weight Change and Body Constitutions of Traditional Chinese Medicine in Patients with SchizophreniaOlanzapine in Chinese patients with schizophrenia or bipolar disorder: a systematic literature review.Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study.Weight gain and glucose dysregulation with second-generation antipsychotics and antidepressants: a review for primary care physicians.Efficacy of olanzapine long-acting injection in patients with acutely exacerbated schizophrenia: an insight from effect size comparison with historical oral data.Determination of olanzapine and N-desmethyl-olanzapine in plasma using a reversed-phase HPLC coupled with coulochemical detection: correlation of olanzapine or N-desmethyl-olanzapine concentration with metabolic parameters.Metformin and berberine prevent olanzapine-induced weight gain in ratsAssociation of Allelic Variation in Genes Mediating Aspects of Energy Homeostasis with Weight Gain during Administration of Antipsychotic Drugs (CATIE Study).Acute Metabolic Effects of Olanzapine Depend on Dose and Injection Site.Misclassification in assessment of diabetogenic risk using electronic health records.Comparison of the effects of Sertindole and Olanzapine on Cognition (SEROLA): a double-blind randomized 12-week study of patients diagnosed with schizophrenia.Olanzapine-fluoxetine combination for the treatment of bipolar depression.Treatment-emergent adverse events associated with atypical antipsychotics.Orally disintegrating olanzapine review: effectiveness, patient preference, adherence, and other properties.Efficacy of olanzapine in comparison with clozapine for treatment-resistant schizophrenia: evidence from a systematic review and meta-analyses.New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia.The efficacy and safety of switching to ziprasidone from olanzapine in patients with bipolar I disorder: an 8-week, multicenter, open-label study.The prevention of diabetes and cardiovascular disease in people with schizophrenia.Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management.Intrinsic and Antipsychotic Drug-Induced Metabolic Dysfunction in Schizophrenia.Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013.Genetic Correlation Profile of Schizophrenia Mirrors Epidemiological Results and Suggests Link Between Polygenic and Rare Variant (22q11.2) Cases of Schizophrenia.Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters.Role of olanzapine in chemotherapy-induced nausea and vomiting on platinum-based chemotherapy patients: a randomized controlled study.Decreased 5-HT2cR and GHSR1a interaction in antipsychotic drug-induced obesity.The effect of reboxetine co-administration with olanzapine on metabolic and endocrine profile in schizophrenia patients.Long-acting injectable antipsychotics update: lengthening the dosing interval and expanding the diagnostic indications.
P2860
Q27331464-E30F6C55-1FCB-4108-9F82-4C7BF482C7ACQ30353864-7E004B4E-2618-43B6-B913-F3E532C22EA7Q30370448-5C2AE1D9-34A7-4A7D-8411-29F7FC2AABAAQ33680103-1DC5FE53-A4F2-47F9-96EC-A96702C69196Q33826250-FD9A36FA-6FC4-4A9B-9B42-B67F2E86D4E7Q34033259-1CDC0E54-CF2F-4CA1-A9BA-5CD038156F04Q34286350-865EED85-8938-4C7A-895D-8C8169CCB707Q34761472-9C1FA5CC-F267-4EAB-BFBC-B39858D7D9BAQ35131343-0D7E2C10-5C30-4C10-879D-16A29DA01DABQ35460642-35DCE21D-4BAE-4854-98D0-C6018DAFEC0CQ36371905-3B4CF94E-DAEE-465A-89DB-A0DA9EB6AAE4Q37233836-7D780DDC-A77C-4B34-8CA6-317C67D83B7AQ37494981-0C482B22-04C8-4258-883E-18F1EE2AA9A6Q37950471-184DAAAC-CCC8-47D8-875D-02A1031DEE36Q37981271-319808FE-F31B-4C08-856B-DA4EC6126EADQ37985887-A5F48452-EE13-4FCB-96AA-9835D8F2F501Q38068636-BB5AA0D4-71C6-4651-B72F-85DB54BE0EBDQ38125213-7AE8908A-595E-456B-BF9F-E34650A361B6Q38132709-310B0061-26FE-4B58-A189-E574C89DCF1CQ38482029-738CBDE7-4E49-443F-8262-B9DA4B0ADB88Q38504254-265BBCBE-3542-452F-BEDC-BC632502DF4CQ38626655-434B0BB6-04B2-40BD-B5C0-1BA1C6E5CE9FQ44142664-B818F524-A30E-4F78-84CA-C3620BA1B740Q47222544-F7B9709F-AD3A-47C8-B4FC-EF9C5F585E1FQ47332928-5D016220-5943-4A67-932E-DBA20C5F7BCEQ47664267-0F29A8C3-C4F6-48DD-955E-8BDD38ABC46BQ48336234-42E7C70E-C879-4E4D-8770-A7CA561575CBQ50701935-155AA3C8-D5A7-484E-AE8C-F8AB65A284C8Q54217848-6B4A8847-6C2A-4110-88B6-95187D69F76B
P2860
Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Weight gain and changes in met ...... ophrenia and bipolar disorder.
@en
Weight gain and changes in met ...... ophrenia and bipolar disorder.
@nl
type
label
Weight gain and changes in met ...... ophrenia and bipolar disorder.
@en
Weight gain and changes in met ...... ophrenia and bipolar disorder.
@nl
prefLabel
Weight gain and changes in met ...... ophrenia and bipolar disorder.
@en
Weight gain and changes in met ...... ophrenia and bipolar disorder.
@nl
P2860
P921
P1476
Weight gain and changes in met ...... zophrenia and bipolar disorder
@en
P2093
Daniel J Walker
Vicki Poole Hoffmann
P2860
P304
P356
10.2165/11589060-000000000-00000
P577
2011-01-01T00:00:00Z